Global Statistics

spot_img

Clinical Trial Updates

Clinical Trial Updates

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting...
Danielle Garcia -
Clinical Trial Updates

IASO Bio’s Anti-GPRC5D CAR T-Cell RD118 Shows Promising Results in Relapsed/Refractory Multiple Myeloma

IASO Biotherapeutics, a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that the Blood published the...
Danielle Garcia -
Clinical Trial Updates

Results of a First-in-Human Study Demonstrates Feasibility of In Vivo CAR T-Cell Therapy in Systemic Lupus Erythematosus

The first clinical data for an mRNA-lipid nanoparticle (mRNA-LNP)- based in vivo CAR T-cell candidate, HN2301*, developed by MagicRNA, were published in The New...
Danielle Garcia -

Recent Articles

Stay on op - Ge the daily news in your inbox

spot_img

The Journal of CAR T-Cell Therapy is an international science & medicine-focused news publication designed to serve the needs of a diverse community, including academia, life sciences, pharma, clinical research, clinicians, and physicians. Along with global clinical and regulatory news, we also cover payor and policy-related news and updates.

© Copyright 2025 Sunvalley Communication, LLC

Quick Links

Must Read

Popular Articles